Astellas Pharma Inc. - ADR
ALPMY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.26B
Close$
$48.53
188.1% upside
Current Fair Value
188.1% upsideUndervalued by 188.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $30.26 Billion |
|---|---|
| Enterprise Value | $216.95 Billion |
| Annual dividend | $0.45 |
| Dividend yield | 2.93% |
| Earnings per Share | $172.56 |
| Beta | 0.09 |
| Outstanding Shares | 1,796,175,000 |
Return
| Return on Equity | 20.36% |
|---|---|
| Return on Assets | 11.44% |
| Return on Invested Capital | 24.23% |
Valuation & Multiples
| P/E Ratio | 12.54 |
|---|---|
| PEG | 0.07 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.02 |
| Enterprise Value to Revenue | 0.09 |
| Enterprise Value to EBIT | 0.37 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 1.96 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS
$0.35
Est. $0.41Revenue
$3.99 B
Est. $3.79 BNext Earnings Call
Expected Date
February 3, 2027
EPS Estimate
$0.38
Consensus analyst estimateRevenue Estimate
$3.89 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Astellas Pharma Inc.
14,099 employees
CEO: Kenji Yasukawa
Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. ...